Oncology News

Oncology

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Herrera M et al. – The more common approach to comet assay studies with cancer patients involves indirect measurement of the effect of antineoplastic drug or radiation regimen by assessing DNA damage in surrogate cells, such as peripheral blood lymphocytes of cancer patients, to predict how tumor cells may be affected. The aim of the present study was to compare the capability of different cells isolated from a series of 23 colon cancer patients to repair the damage induced by a cancer drug. The data support the view that lymphocyte repair activity is not predictive of the repair ability of the tumor and that lymphocytes cannot act as surrogate cells.

Related Articles

Unusual Metals Could Forge New Cancer Drug
ScienceDaily, 10/20/09    Relevance Score: 70%

Management of Primary Colon Cancer in Older Adults
Geriatrics & Aging, 10/12/09    Relevance Score: 70%

Estimated dose to the rectum and colon in prostate cancer patients treated with exclusive radiation therapy presenting a secondary colorectal malignancy
Clinical Oncology, 10/07/09    Relevance Score: 70%

Selective activation of tumor growth-promoting Ca2+ channel MS4A12 in colon cancer by caudal type homeobox transcription factor CDX2
Molecular Cancer, 10/02/09    Relevance Score: 70%

Plasma enterolactone and risk of colon and rectal cancer in a case–cohort study of Danish men and women
Cancer Causes and Control, 10/28/09    Relevance Score: 69%


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address